NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Receptor, Epidermal Growth Factor
  • Skin Diseases

abstract

  • This NCCN Task Force Report describes the management of dermatologic and ocular toxicities that occur in patients treated with epidermal growth factor receptor (EGFR) inhibitors. Task force members are from NCCN member institutions and include oncologists, dermatologists, an ophthalmologist, and a mid-level oncology provider. This report describes commonly used therapies that the task force agreed are appropriate standards of care for dermatologic and ophthalmologic toxicities associated with EGFR inhibitors, which generally are supported only by anecdotal evidence. Few recommendations are evidence based; however, some commonly used therapies have data supporting their use. Conclusions from completed clinical trials are generally limited by the small numbers of patients enrolled. The information in this report is based on available published data on treating toxicities associated with EGFR inhibitors, data from treatment of clinically similar toxicities from different etiologies, and expert opinion among the NCCN Task Force members.

publication date

  • May 2009

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 19470276

Additional Document Info

start page

  • S5

end page

  • 21; quiz S22-4

volume

  • 7

number

  • SUPPL. 1